Andrew McGovern

4.7k total citations
85 papers, 2.4k citations indexed

About

Andrew McGovern is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Epidemiology. According to data from OpenAlex, Andrew McGovern has authored 85 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Endocrinology, Diabetes and Metabolism, 12 papers in Surgery and 12 papers in Epidemiology. Recurrent topics in Andrew McGovern's work include Diabetes Treatment and Management (34 papers), Diabetes Management and Research (19 papers) and Metabolism, Diabetes, and Cancer (8 papers). Andrew McGovern is often cited by papers focused on Diabetes Treatment and Management (34 papers), Diabetes Management and Research (19 papers) and Metabolism, Diabetes, and Cancer (8 papers). Andrew McGovern collaborates with scholars based in United Kingdom, United States and Australia. Andrew McGovern's co-authors include Simon de Lusignan, Neil Munro, Simon Jones, William Hinton, John Dennis, Ana Correa, Martin Whyte, Jeremy van Vlymen, Bilal A. Mateen and Sebastian J. Vollmer and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Andrew McGovern

80 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrew McGovern United Kingdom	27	847	390	375	326	245	85	2.4k
Martin Whyte United Kingdom	24	711 0.8×	321 0.8×	578 1.5×	329 1.0×	325 1.3×	133	2.4k
Edward Chia‐Cheng Lai Taiwan	28	514 0.6×	573 1.5×	408 1.1×	294 0.9×	145 0.6×	162	3.1k
John‐Michael Gamble Canada	24	757 0.9×	334 0.9×	248 0.7×	292 0.9×	142 0.6×	81	1.8k
Abbas Kezouh Canada	25	403 0.5×	758 1.9×	572 1.5×	219 0.7×	367 1.5×	49	3.0k
Mihaela Stefan United States	30	338 0.4×	482 1.2×	375 1.0×	473 1.5×	300 1.2×	134	3.4k
Phil McEwan United Kingdom	37	1.9k 2.2×	745 1.9×	691 1.8×	421 1.3×	166 0.7×	205	4.5k
Shih‐Chieh Shao Taiwan	24	416 0.5×	403 1.0×	377 1.0×	260 0.8×	124 0.5×	94	2.3k
Alexander Kutz Switzerland	29	438 0.5×	965 2.5×	409 1.1×	181 0.6×	552 2.3×	108	2.7k
Jan A. Hazelzet Netherlands	42	517 0.6×	1.6k 4.2×	502 1.3×	269 0.8×	137 0.6×	136	4.5k

Countries citing papers authored by Andrew McGovern

Since Specialization

Citations

This map shows the geographic impact of Andrew McGovern's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew McGovern with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew McGovern more than expected).

Fields of papers citing papers by Andrew McGovern

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew McGovern. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew McGovern. The network helps show where Andrew McGovern may publish in the future.

Co-authorship network of co-authors of Andrew McGovern

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew McGovern. A scholar is included among the top collaborators of Andrew McGovern based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew McGovern. Andrew McGovern is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Richard, Jennifer E., Andrew McGovern, Stephanie E. Lieblich, et al.. (2025). Sex-specific metabolic and central effects of GLP-1–estradiol conjugate in middle-aged rats on a standard or western diet. Brain Behavior and Immunity. 130. 106088–106088.

Young, Katherine, Andrew McGovern, Beverley M. Shields, et al.. (2025). Precision medicine in type 2 diabetes: targeting SGLT2 inhibitor treatment for kidney protection. Diabetologia. 69(2). 374–385. 1 indexed citations

Young, Katherine, Nicholas J. Thomas, Bilal A. Mateen, et al.. (2024). Risk factor associations for severe COVID-19, influenza and pneumonia in people with diabetes to inform future pandemic preparations: UK population-based cohort study. BMJ Open. 14(1). e078135–e078135. 6 indexed citations

Thomas, Nicholas J., Robert Challen, Angus G. Jones, et al.. (2024). Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approach. Diabetologia. 67(9). 1817–1827. 9 indexed citations

Young, Katherine, Anand Thakarakkattil Narayanan Nair, Andrew McGovern, et al.. (2024). Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Diabetologia. 67(5). 822–836. 12 indexed citations

Young, Katherine, Andrew McGovern, Inês Barroso, et al.. (2022). The impact of population-level HbA1c screening on reducing diabetes diagnostic delay in middle-aged adults: a UK Biobank analysis. Diabetologia. 66(2). 300–309. 4 indexed citations

Thomas, Nicholas J., Andrew McGovern, Katherine Young, et al.. (2022). Identifying type 1 and 2 diabetes in research datasets where classification biomarkers are unavailable: assessing the accuracy of published approaches. Journal of Clinical Epidemiology. 153. 34–44. 14 indexed citations

Lusignan, Simon de, Helen Alexander, John Dennis, et al.. (2022). Atopic dermatitis and risk of autoimmune conditions: Population-based cohort study. Journal of Allergy and Clinical Immunology. 150(3). 709–713. 40 indexed citations

Lusignan, Simon de, Andrew McGovern, William Hinton, et al.. (2022). Barriers and Facilitators to the Initiation of Injectable Therapies for Type 2 Diabetes Mellitus: A Mixed Methods Study. Diabetes Therapy. 13(10). 1789–1809. 8 indexed citations

10.

Mateen, Bilal A., John Dennis, Andrew J. Duncan, et al.. (2021). Hospital bed capacity and usage across secondary healthcare providers in England during the first wave of the COVID-19 pandemic: a descriptive analysis. BMJ Open. 11(1). e042945–e042945. 26 indexed citations

11.

McGovern, Andrew, Nicholas J. Thomas, Sebastian J. Vollmer, et al.. (2021). The disproportionate excess mortality risk of COVID-19 in younger people with diabetes warrants vaccination prioritisation. Diabetologia. 64(5). 1184–1186. 14 indexed citations

12.

Dennis, John, et al.. (2021). A national retrospective study of the association between serious operational problems and COVID-19 specific intensive care mortality risk. PLoS ONE. 16(7). e0255377–e0255377. 2 indexed citations

13.

Dennis, John, Andrew McGovern, Sebastian J. Vollmer, & Bilal A. Mateen. (2020). Improving Survival of Critical Care Patients With Coronavirus Disease 2019 in England: A National Cohort Study, March to June 2020*. Critical Care Medicine. 49(2). 209–214. 101 indexed citations

14.

McGovern, Andrew, Michael A. Hogg, Beverley M. Shields, et al.. (2020). Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. BMJ Open Diabetes Research & Care. 8(1). e001238–e001238. 62 indexed citations

15.

Dennis, John, William Henley, Andrew McGovern, et al.. (2019). Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010–2017. Diabetes Obesity and Metabolism. 21(7). 1576–1584. 68 indexed citations

16.

Whyte, Martin, William Hinton, Andrew McGovern, et al.. (2019). Disparities in glycaemic control, monitoring, and treatment of type 2 diabetes in England: A retrospective cohort analysis. PLoS Medicine. 16(10). e1002942–e1002942. 66 indexed citations

17.

Lusignan, Simon de, et al.. (2018). Glycemic control is an important modifiable risk factor for uveitis in patients with diabetes: A retrospective cohort study establishing clinical risk and ophthalmic disease burden. Journal of Diabetes and its Complications. 32(6). 602–608. 18 indexed citations

18.

Whyte, Martin, Andrew McGovern, Janet van Vlymen, et al.. (2018). Does baseline HbA1c or change in HbA1c predict the reduction in cardiovascular death with empagliflozin? Results from EMPA-REG OUTCOME. Diabetic Medicine. 35. 95–96. 1 indexed citations

19.

McGovern, Andrew, Jenny Woodman, Jeremy van Vlymen, et al.. (2015). A simple clinical coding strategy to improve recording of child maltreatment concerns: an audit study. Journal of Innovation in Health Informatics. 22(1). 227–234. 6 indexed citations

20.

McGovern, Andrew, et al.. (2014). Dapagliflozin: Clinical practice compared with pre-registration trial data. The British Journal of Diabetes. 14(4). 138–138. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact